

REMARKS

Claims 1, 2, 4-8 and 10 were pending in the present application before the amendment as set forth above. By this Amendment, claim 6 is amended, and claims 1, 2, 4 and 5 are canceled.

In the Office Action dated July 13, 2010, claim 1, 2, 4 and 5 stand rejected under 35 U.S.C. § 102(b), as being anticipated by Prasad et al. (Journal of Cell Science, October 1, 2002, vol. 115, pp. 3807-3815) as evidenced by Invitrogen Product Data Sheet.

However, the Examiner indicated that claims 6-8 and 10 are allowable.

Applicant appreciates the Examiner's careful review of the application and allowability of claims 6-8 and 10.

In response, as set forth above, claim 6 has been rewritten, according to the Examiner's suggestion (e.g., in the April 15, 2010 Office Action), in the independent form that includes all of the limitation of the base claim, now canceled claim 1, which makes amended claim 6 in condition for allowance. Accordingly, claims 7, 8 and 10, which depend from claim 6, are also in condition for allowance.

Claims 1, 2, 4 and 5 have been canceled, which makes the 35 U.S.C. §102 rejections to claims 1, 2, 4 and 5 moot.

No new matter is added.

It is now believed that the application is in condition for allowance and such allowance is respectfully requested.

CONCLUSION

Applicant respectfully submits that the foregoing Response place this application in condition for allowance. If the Examiner believes that there are any issues that can be resolved by a telephone conference, or that there are any informalities that can be corrected by an Examiner's amendment, please call the undersigned at 404-495-3678.

Respectfully submitted,

MORRIS, MANNING & MARTIN, LLP

October 26, 2010



Tim Tingkang Xia
Attorney for Applicant on the Record
Reg. No. 45,242

MORRIS, MANNING & MARTIN, LLP
1600 Atlanta Financial Center
3343 Peachtree Road, N.E.
Atlanta, Georgia 30326-1044
Phone: 404-233-7000
Direct: 404-495-3678
Customer No. 24728